Place of angiotensin receptor blockers in antihypertensive therapy
Abstract
The arterial hypertension takes the basic place among the cardiovascular diseases which are a principal cause of death and invalidity. For today the basic group for treatment of an arterial hypertensia remain angiotensin-converting enzyme inhibitors (ACEi). However, according to numerous researches, angiotensin II receptor inhibitors by the efficiency are equal with ACEi, but have the best profile of shipping and provide higher adherence to therapy. One of highly effective, well studied, with considerable demonstrative base of preparations irbesartan.
About the Authors
A. I. Martynov
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
Russian Federation
Russian Federation
I. V. Urlaeva
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
Russian Federation
Russian Federation
E. V. Akatova
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
Russian Federation
Russian Federation
O. P. Nikolin
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
Russian Federation
Russian Federation
References
1. Диагностика и лечение артериальной гипертензии. Кардиоваск. терапия и профилактика. 2008; 7 (6). Прил. 2.
2. ESH-ESC Guidelines Committee. 2007 Guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.
3. Neutel J et al. Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild - to - Moderate Hypertension.J RAAS 2005; 6: 84-9.
4. Mimran A et al. A rindomised, double - blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild - to - moderate hypertension. J Hum Hypertens 1998; 12: 203-8.
5. Stumpe K.O et al. Comparison of the Angiotensin II Receptor Antagonist Irbesartan With Atenolol for Treatment of Hypertension Blood Press 1998; 7: 31-7.
6. Mancia G et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efcacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135-42.
7. Kassler-Taub K et al. Comparative Efcacy of Two Angiotensin II Receptor Antagonist, Irbesartan and Losartan, in Mild - to - Moderate Hypertension. Am J Hypertens 1998; 11: 445-53.
8. Fogari R et al. 24-Hour blood pressure control by once - daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511-8.
9. Neutel J.M et al. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. J Hypertens 2006; 24: S284.
10. Parving H.H, Lehnert H, Brochner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
11. Lewis E.J, Hunsicker L.G, Clarke W.R et al. Renoprotective effect of the angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
12. Madrid A.H, Marнn I.M, Cervantes C.E et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose - dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5 (3): 114-20.
13. Larochelle P et al. for the Irbesartan Multicenter Investigators. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol 1997; 80: 1613-5.
14. Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
15. Neutel J.M, Saunders E, Bakris G.L et al. INCLUSIVE Investigators. The efficacy and safety of low - and high - dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7 (10): 578-86.
16. Kohar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild - to - moderate hypertension. Am J Hypertens 1999; 12: 797-805.
17. Hasford J et al. A population - based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569-75.
Review
For citations:
Martynov A.I., Urlaeva I.V., Akatova E.V., Nikolin O.P. Place of angiotensin receptor blockers in antihypertensive therapy. Systemic Hypertension. 2014;11(1):34-39. (In Russ.)
Views:
94
Email this article 